🇺🇸 FDA
Patent

US 7329502

ZAP-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

granted A61PA61P35/02

Quick answer

US patent 7329502 (ZAP-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Feb 07 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Feb 12 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 07 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61P, A61P35/02